Imperial Bioscience Ltd, a leading biopharmaceutical company, is proud to announce that it has been awarded a substantial grant under the Biomedical Catalyst 2023 Programme by Innovate UK. This recognition is a testament to the exceptional translational research activities conducted by Imperial Bioscience in the field of Microarray Patches (MAPs). The grant award, totalling £0.5 million, will further propel the development of Imperial Bioscience’s innovative MPT platform.

 

The grant enables Imperial Bioscience to apply its cutting-edge technology to the development of medicinal products. The project's primary goal is to complete the pre-clinical phase and transition into the clinical stage, focusing on addressing skin concerns such as acne management.

 

Innovate UK, a part of UK Research and Innovation invests in innovation projects that aim to tackle significant health or healthcare challenges. The Biomedical Catalyst programme's industry-led research and development (R&D) stream specifically supports pre-market R&D projects demonstrating clear commercial and technical feasibility. It is a prestigious and highly competitive funding program dedicated to assisting small and medium-sized enterprises (SMEs) in their research and development endeavours.

 

Imperial Bioscience’s Microneedle Patch Technology has already made significant advancements in the cosmetic industry through its Luna Microcare product line. The technology also holds great promise for a wide range of applications in the pharmaceutical sector, particularly in the development of combination products.

 

Dr. Avcil, CEO of Imperial Bioscience, expressed his pleasure upon receiving this prestigious grant, emphasising the technology's tremendous potential in advancing drug delivery. He looks forward to witnessing the future advancements that Imperial Bioscience will achieve in this field.

 

For business development inquiries, please get in touch with us at

info@imperialbioscience.co.uk

 

About Imperial Bioscience

Imperial Bioscience is a biopharmaceutical company committed to developing and commercialising innovative therapeutics to provide life-enhancing treatments. Traditional methods of delivering drug substances (active ingredients) into the human body include orally administered medicines, injections, ointments, and patches. The "dissolving microstructure"; developed, produced, and commercialised by Imperial Bioscience has enhanced the existing drug delivery system, making it safer, more convenient, and more efficient in the delivery of active ingredients.

​

For more information about Imperial Bioscience, please visit our website:

https://www.imperialbioscience.co.uk